AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Sales of Investments

Cash received from selling or redeeming investments.

AC Immune S.A.NASDAQ: ACIU

Sales of Investments · Q4 FY2025 · quarter ended Dec 2025

Sales of investments outflow grows to CHF 16.05M

Q4 FY2025 sales of investments was CHF 16.05M, compared with CHF 0 a year earlier. Trailing-twelve-month sales of investments was CHF 16.05M.

Context

  • Sales of investments amounted to 1726.6% of revenue in FY2025, up 1726.6 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly sales of investments holds near CHF 16.05M or moves back toward the trailing-twelve-month quarterly average of CHF 4.01M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
CHF 16.05M— QoQ
Last fiscal yearDec 2025
CHF 61.69M— YoY
LTMDec 2025
CHF 16.05M— YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

CHF · from the cash flow

Latest · FY2025
61.69M CHF
Year-over-year change
—

Sales of Investments vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Sales of investments amounts to 449.1% of revenue for ACIU, versus a peer median of 285.2%.
ACIU Competitors
Sales of Investments for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$275.9M USD-45.0%+31.2%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$275.21M USD-52.0%-3.7%887777.4%
AMRNAmarin Corporation plcLTM Mar 2026$196.48M USD-13.0%-6.6%91.4%
CLLSCellectis S.A.LTM Mar 2026$194.21M USD+230.8%+921.3%285.2%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$168.49M USD+1.3%+22.2%—
SLNSilence Therapeutics plcLTM Mar 2026$101.74M USD——11040.3%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$65M USD-13.3%+11.8%—
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$55.98M USD———
ACIUAC Immune S.A.LTM Dec 2025CHF 16.05M CHF——449.1%
ANROAlto Neuroscience, Inc.LTM Mar 2026$0 USD———
MREOMereo BioPharma Group plcLTM Mar 2026$0 USD——0.0%
Peer median (excluding ACIU) —-13.2%+17.0%285.2%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.